SUMMARY Soft tissue sarcomas (STS) represent a diverse group of histologic subtypes with targetable molecular alterations, often treated as a single disease. Sunitinib malate is a multitargeted receptor tyrosine kinase inhibitor active in other solid tumors carrying similar alterations (i.e., imatinib mesylate-refractory gastrointestinal stromal tumors). This single-institution phase II study investigated the safety and efficacy of sunitinib malate in three common STS subtypes. Patients with documented unresectable or metastatic STS (liposarcoma, leiomyosarcoma, and malignant fibrous histiocytoma [MFH]), measurable disease, and 3 or less prior lines of therapy were eligible. Treatment consisted of sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks. Forty-eight patients were enrolled, and 35% were heavily pretreated (≥2 prior lines of chemotherapy). The safety profile resembled previously known sunitinib malate toxicities. Median progression-free and overall survivals for liposarcoma, leiomyosarcoma, and MFH were 3.9 and 18.6, 4.2 and 10.1, and 2.5 and 13.6 months, respectively. The 3-month progression-free rates in the untreated and pretreated (chemotherapy) patients with liposarcoma, leiomyosarcoma, and MFH were 75% and 69.2%, 60%, and 62.5%, and and 25% and 44.4%, respectively. With the caveats that a minority of patients with potentially indolent or low-grade disease could have been included and the small numbers, a 3-month progression-free rate of >40% suggests activity for sunitinib malate at least in liposarcomas and leiomyosarcomas. Thus, we believe that further investigation in these susceptible STS subtypes is warranted.

No abstract

DOI: http://dx.doi.org/10.3329/jafmc.v8i2.16357 JAFMC Vol.8(2) 2012 pp.64-69

This abstract was not presented at the symposium.

Cu2ZnSnS4 (CZTS) thin films are fabricated on glass substrates using the spray pyrolysis method with different concentrations of Sn content were studied in this research work. All the CZTS thin films are fabricated at substrate temperature 200°C to minimize the formation of secondary phases. Here, we show how the variation in Sn content concentration influences the optical and structural properties of the CZTS thin films. The XRD patterns reveal that the concentration of Sn content has to be optimized to minimize the formation of secondary phases for a fixed substrate temperature. In turn, the band gap of the CZTS films is highly influenced by the formation of secondary phases. We have found that the films prepared from the precursor solution with 1.8 mM concentration of Sn content have the best crystal structure and an optical band gap of 1.55 eV. The CZTS thin films also have good carrier concentrations ranging from 4.2×1019 to 22.9×1020 cm-3. Bangladesh J. Sci. Ind. Res. 57(1), 1-6, 2022